Tampa firm pulls entire 10 Day Forecast line after FDA finds hidden drugs

Game Changer Products, a Tampa, Florida company, is withdrawing its 10 Day Forecast capsules from the US market down to consumer level. The recall covers every lot, so no batch of the product is left outside it. The company announced the move on 12 November 2026, and FDA listed it on its MedWatch recalls page the same day.

The recall follows FDA laboratory analysis that found sildenafil and acetaminophen in the capsules, though neither is named on the packaging. Sildenafil is the active ingredient of an FDA-approved prescription erectile dysfunction medicine. Acetaminophen is a common pain and fever treatment. Because the capsules contain these substances, the notice treats them as drugs that have not been approved, with safety and efficacy unestablished, rather than as a legitimate over-the-counter nutritional product.

The notice names two main hazards. Sildenafil can interact with nitrates such as nitroglycerin and cause a sharp, potentially life-threatening drop in blood pressure, and men who take nitrates for heart conditions face the greatest risk. Acetaminophen the user does not know about could add to their usual dose, with liver injury ranging from mild to fatal, plus anaphylaxis and severe skin reactions. The company says it has received no adverse event reports tied to the product.

The notice gives distribution details but no sales volumes or financial impact. Product was sold nationwide, including in Puerto Rico, Guam and the Northern Mariana Islands, from at least October 2021 to 17 October 2026. Channels were the company's own website, eBay and one retail store in Minnesota. Customers are being told by email and eBay messages, and the store by letter. The capsules come on cards holding one or two blue capsules, with UPC 191645852717, a black background and white lettering. Lot numbers and expiry dates are printed on the back of each card. Consumers are asked to stop using the product and dispose of it safely, and FDA invites reports of adverse reactions through MedWatch.